Polyethylene Glycol Polyester Block Copolymers: Biocompatible Carriers for Nanoparticulate Drug Delivery - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 51

concentrations of drug were loaded, as has been seen with other
drugs (fenofibrate and amiodarone) in PEO-PCL micelles [22, 41].
As shown in Table 3.2, the micelle size generally increases when the
hydrophobic solute (drug) is retained in the core. This is expected
as the PCL chains in the core will have a relatively small free volume
(due to their crystallinity), and the inclusion of drug molecules will
increase the core size, and thus the micelle size.

Table 3.2 Influence of encapsulated drug on PEO-PCL micelle size

PEO
MW
(kDa)

PCL
MW
(kDa)

Drug Encapsulation

efficiency (%)

Micelle
size
without
drug
(nm)

Micelle
size
with
drug
(nm)

Ref.

5.0 6.2 indomethacin 40 130 165 [40]

5.0 1.0 fenofibrate 29 19 22 [22]

5.0 2.5 fenofibrate 95 22 24 [22]

5.0 4.0 fenofibrate 92 33 41 [22]

5.0 5.0 CsA 52 88 100 [45]

5.0 13 CsA 64 79 99 [45]

5.0 24 CsA 50 100 102 [45]

2.0 2.0 DOX n/a 17 25 [25]

5.0 2.5 DOX n/a 30 23 [25]

5.0 5.0 DOX n/a 41 37 [25]

5.0 8.5 DOX n/a 57 84 [25]

5.0 25 DOX n/a 86 105 [25]

5.0 6.0 rapamycin 24 31 48 [60]

5.0 6.0 rapamycin
+ 1:20
α-tocopherol

50 63 44 [60]

5.0 10 rapamycin 50 79 76 [60]

5.0 10 rapamycin
+ 1:20
α-tocopherol

73 109 107 [60]

5.0 18 rapamycin 31 40 46 [60]

5.0 18 rapamycin
+ 1:20
α-tocopherol

66 57 44 [60]